http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-112015025304-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f52c68e4149a6c462b850d4e7cc2b2f9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-277 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-277 |
| filingDate | 2014-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdcd8f069ef5f3fa028800cd75bfede9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cfdf9ed8644423b7f4f51fec6739882 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15f898ea16788dbc1b3b9ae35e09a6c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f532ba2ffde0e194af8e32b850d0e812 |
| publicationDate | 2017-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-112015025304-A2 |
| titleOfInvention | use of substituted 2,3-dihydroimidazo [1,2-c] quinazolines for treatment of lymphomas |
| abstract | summary use of substituted 2,3-dihydroimidazo [1,2-c] quinazolines for treatment of lymphomas. The present invention relates to: Use of a 2,3-dihydroimidazo [1,2-c] quinazoline compound or pharmaceutical composition containing the same as a sole active agent or a combination of a) o cited compound or a pharmaceutical composition containing compound and b) one or more active agents for the manufacture of a medicament for the treatment or prophylaxis of non-hodgkin lymphoma (nhl), particularly first-line, second-line, relapsed non-hodgkin (nhl) lymphoma refractory, indolent or aggressive, in particular follicular lymphoma (fl), chronic lymphocyte leukemia (cll), marginal zone lymphoma (mzl), diffuse large b-cell lymphoma (dlbcl), mantle cell lymphoma (mcl), lymphoma transformed (tl) or peripheral t-cell lymphoma (ptcl); - combinations of a) said compound and b) one or more active agents; a pharmaceutical composition consisting of a compound as a single active agent for the treatment of non-hodgkin's lymphoma (nhl), particularly first-line, second-line, relapsed, refractory, indolent or aggressive lymphoma, in particular lymphoma follicular (fl), chronic lymphocyte leukemia (cll), marginal zone lymphoma (mzl), diffuse large b-cell lymphoma (dlbcl), mantle cell lymphoma (mcl), transformed lymphoma (tl) or peripheral t-cell lymphoma (ptcl); a pharmaceutical composition of a) said compound and b) one or more active agents; - use of biomarkers involved in modifying the expression of isoforms pi3k, btk and ikk, bcr activation, downward activation of nfkb, c-myc, ezh2 pathway bcr to predict the sensitivity and / or resistance of a cancer patient to the compound cited and provide a synergistic combination based on argumentation as defined herein to increase sensitivity and / or overcome resistance; and - a method of determining the level of one component or more of isoform expression pi3k, btk and ikk, bcr activation, downward activation of pathway bcr nfkb, c-myc, ezh2. 1/2 |
| priorityDate | 2013-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.